Sort   by:  
 Page size 
UnknownBEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Not available
S-EPMC4500832 | biostudies-literature
UnknownQuality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Not available
S-EPMC5891128 | biostudies-literature
UnknownAbiraterone in prostate cancer: a new angle to an old problem.
Not available
S-EPMC3761800 | biostudies-literature
UnknownChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Not available
S-EPMC5891129 | biostudies-literature
UnknownBcl-2 modulation to activate apoptosis in prostate cancer.
Not available
S-EPMC2855683 | biostudies-literature
UnknownImmune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Not available
S-EPMC4887167 | biostudies-literature
UnknownUse of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Not available
S-EPMC5796528 | biostudies-literature
UnknownClinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Not available
S-EPMC5189630 | biostudies-literature
UnknownBMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.
Not available
S-EPMC5159329 | biostudies-literature
Sort   by:  
 Page size